JO3466B1 - مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 - Google Patents
مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6Info
- Publication number
- JO3466B1 JO3466B1 JOP/2014/0369A JOP20140369A JO3466B1 JO 3466 B1 JO3466 B1 JO 3466B1 JO P20140369 A JOP20140369 A JO P20140369A JO 3466 B1 JO3466 B1 JO 3466B1
- Authority
- JO
- Jordan
- Prior art keywords
- gpr6
- modulators
- tetrahydropyridopyrazines
- compounds
- intermediates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
يوفر الاختراع الحالي مركبات من الصيغة 1: 1 التي تكون مفيدة كمواد ضابطة (modulators)GPR6، تركيبات دوائية من هذا، طرق لمعالجة حالات مصاحبة مع GPR6، عمليات لصنع المركبات والمركبات الوسطية من هذا.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361919661P | 2013-12-20 | 2013-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3466B1 true JO3466B1 (ar) | 2020-07-05 |
Family
ID=52440811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2014/0369A JO3466B1 (ar) | 2013-12-20 | 2014-12-18 | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
Country Status (41)
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8629274B2 (en) | 2011-12-21 | 2014-01-14 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
WO2014028479A1 (en) | 2012-08-13 | 2014-02-20 | Envoy Therapeutics, Inc. | Quinoxaline derivatives as gpr6 modulators |
JP2015533782A (ja) | 2012-08-28 | 2015-11-26 | ヤンセン・サイエンシズ・アイルランド・ユーシー | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 |
EP2961732B1 (en) | 2013-02-28 | 2017-04-12 | Janssen Sciences Ireland UC | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
MX353412B (es) | 2013-04-03 | 2018-01-10 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
AU2014267235B2 (en) | 2013-05-17 | 2017-10-05 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
KR102290189B1 (ko) | 2013-10-23 | 2021-08-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 카르복스아미드 유도체 및 b형 간염 치료용 의약으로서의 이의 용도 |
JO3466B1 (ar) * | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
CN106232136A (zh) | 2014-02-05 | 2016-12-14 | 诺维拉治疗公司 | 用于治疗hbv感染的联合疗法 |
AU2015214961B2 (en) | 2014-02-06 | 2018-08-30 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2015123505A1 (en) * | 2014-02-14 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Pyridopyrazines modulators of gpr6 |
JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びb型肝炎感染症の治療法 |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
EP3356328A1 (en) | 2015-09-29 | 2018-08-08 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
CN109640980A (zh) | 2016-04-15 | 2019-04-16 | 诺维拉治疗公司 | 包含壳体装配抑制剂的组合和方法 |
JOP20180057A1 (ar) * | 2017-06-15 | 2019-01-30 | Takeda Pharmaceuticals Co | مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 |
WO2019175657A1 (en) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
KR20210130753A (ko) | 2019-02-22 | 2021-11-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체 |
MX2021013594A (es) | 2019-05-06 | 2021-12-10 | Janssen Sciences Ireland Unlimited Co | Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2195768A1 (en) * | 1994-08-11 | 1996-02-22 | Shuji Hinuma | G protein coupled receptor protein, production, and use thereof |
AU6453501A (en) * | 1999-02-26 | 2001-09-03 | Arena Pharmaceuticals, Inc. | Small molecule modulators of G protein-coupled receptor six |
WO2001070269A1 (fr) | 2000-03-24 | 2001-09-27 | Akzo Nobel N.V. | Inhibiteurs de la croissance des keratinocytes et derives d'acide hydroxamique |
AU2003274005A1 (en) * | 2002-10-24 | 2004-05-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6) |
WO2004069162A2 (en) | 2003-01-31 | 2004-08-19 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
SE0400285D0 (sv) * | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
AU2007242555B2 (en) * | 2006-04-21 | 2010-12-16 | Pfizer Products Inc. | Pyridine[3,4-b]pyrazinones |
CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
CA2688471C (en) | 2007-06-05 | 2017-01-17 | Astrium Limited | Remote testing system and method |
GB0710844D0 (en) | 2007-06-06 | 2007-07-18 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
GB2449929A (en) | 2007-06-08 | 2008-12-10 | Snell & Wilcox Ltd | Hierarchical spatial resolution building processes to fill holes in an interpolated image |
JP6041671B2 (ja) | 2009-06-12 | 2016-12-14 | アビバックス | ガンを治療する為に有用な化合物 |
WO2013087808A1 (en) | 2011-12-15 | 2013-06-20 | Merz Pharma Gmbh & Co. Kgaa | Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin |
WO2013087815A1 (en) | 2011-12-15 | 2013-06-20 | Merz Pharma Gmbh & Co. Kgaa | Liquid pharmaceutical composition containing a pyrazolopyrimidine derivative and pharmaceutical uses thereof |
CA2872883A1 (en) | 2012-05-09 | 2013-11-14 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
WO2014028479A1 (en) * | 2012-08-13 | 2014-02-20 | Envoy Therapeutics, Inc. | Quinoxaline derivatives as gpr6 modulators |
FR2995937B1 (fr) | 2012-09-21 | 2014-09-26 | Exoes | Ensemble de production d'electricite a moteur a pression de vapeur |
JO3466B1 (ar) * | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
-
2014
- 2014-12-18 JO JOP/2014/0369A patent/JO3466B1/ar active
- 2014-12-19 RS RS20181548A patent/RS58092B1/sr unknown
- 2014-12-19 ES ES14833425T patent/ES2702187T3/es active Active
- 2014-12-19 CN CN201480069550.7A patent/CN105829309B/zh active Active
- 2014-12-19 TW TW110118089A patent/TWI809395B/zh active
- 2014-12-19 WO PCT/US2014/071543 patent/WO2015095728A1/en active Application Filing
- 2014-12-19 BR BR112016014020-6A patent/BR112016014020B1/pt active IP Right Grant
- 2014-12-19 CA CA2934247A patent/CA2934247C/en active Active
- 2014-12-19 US US14/577,480 patent/US9181249B2/en active Active
- 2014-12-19 KR KR1020167019644A patent/KR102441531B1/ko active IP Right Grant
- 2014-12-19 EP EP14833425.3A patent/EP3083620B1/en active Active
- 2014-12-19 TN TN2016000244A patent/TN2016000244A1/en unknown
- 2014-12-19 MY MYPI2016001142A patent/MY177031A/en unknown
- 2014-12-19 LT LTEP14833425.3T patent/LT3083620T/lt unknown
- 2014-12-19 SG SG11201604921TA patent/SG11201604921TA/en unknown
- 2014-12-19 EA EA201691272A patent/EA032443B1/ru unknown
- 2014-12-19 TR TR2019/00038T patent/TR201900038T4/tr unknown
- 2014-12-19 UY UY0001035908A patent/UY35908A/es not_active Application Discontinuation
- 2014-12-19 AU AU2014368992A patent/AU2014368992C1/en active Active
- 2014-12-19 PE PE2016000838A patent/PE20160751A1/es unknown
- 2014-12-19 CR CR20160321A patent/CR20160321A/es unknown
- 2014-12-19 MX MX2016008188A patent/MX2016008188A/es active IP Right Grant
- 2014-12-19 TW TW103144660A patent/TWI730937B/zh active
- 2014-12-19 PL PL14833425T patent/PL3083620T4/pl unknown
- 2014-12-19 DK DK14833425.3T patent/DK3083620T3/en active
- 2014-12-19 GE GEAP201414210A patent/GEP201706783B/en unknown
- 2014-12-19 NZ NZ721723A patent/NZ721723A/en unknown
- 2014-12-19 AR ARP140104807A patent/AR098872A1/es active IP Right Grant
- 2014-12-19 SI SI201430995T patent/SI3083620T1/sl unknown
- 2014-12-19 CN CN201810356710.6A patent/CN108658978A/zh active Pending
- 2014-12-19 PT PT14833425T patent/PT3083620T/pt unknown
- 2014-12-19 MA MA39193A patent/MA39193B1/fr unknown
- 2014-12-19 HU HUE14833425A patent/HUE042443T2/hu unknown
- 2014-12-19 EP EP18187138.5A patent/EP3453709A1/en not_active Withdrawn
- 2014-12-19 JP JP2016541330A patent/JP6538697B2/ja active Active
- 2014-12-19 UA UAA201606659A patent/UA120427C2/uk unknown
-
2015
- 2015-10-14 US US14/883,174 patent/US9708313B2/en active Active
-
2016
- 2016-06-13 IL IL24617716A patent/IL246177B/en active IP Right Grant
- 2016-06-17 PH PH12016501192A patent/PH12016501192B1/en unknown
- 2016-06-17 DO DO2016000144A patent/DOP2016000144A/es unknown
- 2016-06-20 CL CL2016001595A patent/CL2016001595A1/es unknown
- 2016-07-08 ZA ZA2016/04703A patent/ZA201604703B/en unknown
- 2016-07-20 EC ECIEPI201661758A patent/ECSP16061758A/es unknown
-
2017
- 2017-06-13 US US15/621,761 patent/US10077266B2/en active Active
-
2018
- 2018-08-07 US US16/057,350 patent/US10738046B2/en active Active
- 2018-11-27 HR HRP20182004TT patent/HRP20182004T1/hr unknown
-
2019
- 2019-01-03 CY CY20191100008T patent/CY1121395T1/el unknown
-
2023
- 2023-06-15 AR ARP230101544A patent/AR129635A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501192A1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
PH12018500718A1 (en) | Compounds useful as modulators of trpm8 | |
NZ726859A (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
PH12014502697A1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
PH12018500268A1 (en) | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors | |
JO3719B1 (ar) | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 | |
MX2017007377A (es) | Compuestos organicos. | |
IN2013MU00848A (ar) | ||
EP3795578A3 (en) | Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof | |
MX2018007219A (es) | Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
TW201613934A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
PH12016501613A1 (en) | Pyrazines modulators of gpr6 | |
MX2019002017A (es) | Derivados de sofosbuvir para el tratamiento de la hepatitis c. | |
MX2017007380A (es) | Compuestos organicos. | |
SG10201803880TA (en) | Stable compositions of neuroactive peptides | |
MX338113B (es) | Proceso para la preparacion de polisulfonato de sodio del 5,14-dihidrotetraazapentaceno e intermediarios de los mismos. | |
PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs | |
IN2014MU00197A (ar) | ||
IN2013CH05591A (ar) | ||
IN2013MU01524A (ar) | ||
IN2014MU00069A (ar) | ||
MX2017005669A (es) | Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos. | |
IN2013CH05395A (ar) | ||
IN2013DE03592A (ar) |